ArticleBioImpacts : BI2025
Kopexil vs minoxidil:
Article in BioImpacts : BI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia-A Systematic Review with Network Meta-Analyses.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Dissolving microneedles incorporating kopexil multicomponent crystals for improved transdermal delivery.Drug delivery and translational research · 2026Article
- Microneedle technology integrated with diverse therapeutic modalities for hair regrowth in alopecia.Acta pharmaceutica Sinica. B · 2026Review
- Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation.Aesthetic plastic surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to investigate the impact of a hydro-alcoholic solution containing kopexil on hair growth, and growth factors, and to evaluate its skin penetration, as well as its potential toxic effects on the liver and kidneys in animal models. Methods: Animal studies were conducted on mice over 28 days, involving minoxidil (positive control), kopexil (test), and negative control groups. Morphological characteristics of skin and hair were assessed. Levels of hair growth-promoting markers (HGF and VEGF) were determined through western blot analysis. Toxic effects were examined by isolating and weighing the kidneys and livers, followed by histological examination. Results: The kopexil group demonstrated significant increases in hair weight, follicle count, percentage of anagen hair, and hair growth compared to the minoxidil. Western blot analysis revealed higher expression levels of hair growth-promoting factors in the kopexil-treated group. No statistically significant differences in liver and kidney weights or noticeable morphological variations were observed in the toxicity tests across the groups. Conclusion: The 5% (w/v) hydro-alcoholic solution containing kopexil proved to be an effective hair growth stimulator, influencing various factors. Its daily use can be considered a suitable treatment method for stimulating hair growth, given its improved effectiveness and ease of use for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.